Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize Remogliflozin Etabonate for Type 2 Diabetes in India

Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize Remogliflozin Etabonate for Type 2 Diabetes in India

Shots:

  • Glenmark to receive up front, license fee and royalties on sales and is responsible to manufacture and supply Remogliflozin. Torrent to get rights to commercialize Remogliflozin under the trademark Zucator in India
  • In Apr’2019, Remogliflozin has received CDSCO’s approval following the completion of its P-III studies assessing Remogliflozin vs Dapagliflozin for the treatment of type 2 diabetes mellitus in adults
  • Remogliflozin is the SGLT2 inhibitor act by blocking glucose reabsorption in the kidney further causes the elimination of blood glucose through urine and has been evaluated in 26+ clinical studies globally

Click here to read full press release/ article | Ref: Glenmark | Image: For Press Release